Show simple item record

dc.contributor.authorPinilla, Karen
dc.contributor.authorDrewett, Lynsey M
dc.contributor.authorLucey, Rebecca
dc.contributor.authorAbraham, Jean E
dc.date.accessioned2022-05-31T23:30:43Z
dc.date.available2022-05-31T23:30:43Z
dc.date.issued2022
dc.identifier.issn2234-943X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/337650
dc.description.abstractPersonalised approaches to the management of all solid tumours are increasing rapidly, along with wider accessibility for clinicians. Advances in tumour characterisation and targeted therapies have placed triple-negative breast cancers (TNBC) at the forefront of this approach. TNBC is a highly heterogeneous disease with various histopathological features and is driven by distinct molecular alterations. The ability to tailor individualised and effective treatments for each patient is of particular importance in this group due to the high risk of distant recurrence and death. The mainstay of treatment across all subtypes of TNBC has historically been cytotoxic chemotherapy, which is often associated with off-target tissue toxicity and drug resistance. Neoadjuvant chemotherapy is commonly used as it allows close monitoring of early treatment response and provides valuable prognostic information. Patients who achieve a complete pathological response after neoadjuvant chemotherapy are known to have significantly improved long-term outcomes. Conversely, poor responders face a higher risk of relapse and death. The identification of those subgroups that are more likely to benefit from breakthroughs in the personalised approach is a challenge of the current era where several targeted therapies are available. This review presents an overview of contemporary practice, and promising future trends in the management of early TNBC. Platinum chemotherapy, DNA damage response (DDR) inhibitors, immune checkpoint inhibitors, inhibitors of the PI3K-AKT-mTOR, and androgen receptor (AR) pathways are some of the increasingly studied therapies which will be reviewed. We will also discuss the growing evidence for less-developed agents and predictive biomarkers that are likely to contribute to the forthcoming advances in this field. Finally, we will propose a framework for the personalised management of TNBC based upon the integration of clinico-pathological and molecular features to ensure that long-term outcomes are optimised.
dc.publisherFrontiers Media
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titlePrecision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer-A Review of Molecular Characterisation, Therapeutic Targets and Future Trends.
dc.typeArticle
dc.publisher.departmentDepartment of Oncology
dc.date.updated2022-05-31T12:01:21Z
prism.publicationNameFront Oncol
dc.identifier.doi10.17863/CAM.85056
dcterms.dateAccepted2022-05-23
rioxxterms.versionofrecord10.3389/fonc.2022.866889
rioxxterms.versionAM
dc.contributor.orcidDrewett, Lynsey [0000-0002-2861-1888]
dc.contributor.orcidLucey, Rebecca Elizabeth [0000-0002-6226-447X]
dc.identifier.eissn2234-943X
rioxxterms.typeJournal Article/Review
pubs.funder-project-idNational Institute for Health Research (IS-BRC-1215-20014)
cam.issuedOnline2022-08-08
cam.orpheus.successMon Aug 29 08:26:33 BST 2022 - Embargo updated
cam.orpheus.counter10
cam.depositDate2022-05-31
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
rioxxterms.freetoread.startdate2022-08-08


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International